Diagnostic imaging systems such as CT/PET and MR/PET, which bring together in vivo anatomical and functional information in the same device or at the same workstation, offer a real opportunity for expanding the clinical utility of molecular imaging. But to drive adoption of these new combination systems will require data showing that their use changes therapeutic decision-making. For the most part, these data are at least several years away, with most of the work today in cancer, where in vivo imaging has been shown to better evaluate tumor type, guide radiation therapy, and change chemotherapy management. In the meantime, suppliers of imaging equipment to hospitals and research institutions are collaborating with academics and companies that are developing new radiotracers and other molecular probes. Such moves are not typical for these organizations, which, like IVD companies, traditionally have placed their bets on selling products into mature markets, rather than innovative R&D-oriented projects.
by Mark L. Ratner
A new commercially viable diagnostic imaging modality arrives every ten years or so. In the 1970s it was ultrasound, in...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
